source: BSE

The Far-East Connect Network has many unique network elements that span across the region and comprises of Airtel’s network assets on multiple cables routes i2i, SMW4, APCN2, JUCN, AAG and also a proposed investment in another High Speed Network between Singapore and Japan. This would now enable Bharti Airtel to extend its reach to Australia, Brunei, China, Hong Kong, India, Japan, Malaysia, Singapore, South Korea, Taiwan, Thailand, United States and Vietnam.

According to Manoj Kohli, CEO and Joint Managing Director, Bharti Airtel, “The launch of the “Far-East Connect Network” is another step towards Bharti Airtel’s vision of making Bharti Airtel, the communication services partner of choice for global telcos. Our investments of over US$500 million over the last two years are designed to create a global network that offers unmatched resilience and maximum diversity. Asia and the Pacific represent one of the fastest growing markets for ICT and as industry leaders in India. Bharti Airtel is uniquely positioned to take advantage of this growing market opportunity.”

Through the Far-East Connect Network, Bharti Airtel will be able to deliver seamless connectivity on Asia America Gateway (AAG). Bharti Airtel is one of the leading consortium partners for this new 20,000 Rkms cable system that is now ready to carry commercial traffic. This together with a capacity upgrade by Airtel on its existing network assets on multiple cable routes, has made available an additional 1 Terabit per second of capacity to the region. This Terabit Super Express Highway will link major cable landing stations in India, HK, Japan, Singapore and across the Pacific to the United States.

Further, through a unique partnership model, Airtel has entered into partnerships for capacity and onward connectivity to Japan, Taiwan, Australia and South Korea through multiple alternate routes. The initiative is consistent with Airtel’s aim of ensuring diverse meshed cable topologies on all major routes.

Bharti Airtel’s, global wholesale portfolio offers MPLS, Ethernet, IP and International Private Leased Circuit (IPLC) services to carriers in high growth markets across Asia and the Pacific. The portfolio includes solutions for voice and data connectivity, collaboration services, co-location, carrier outsourcing and content distribution through its next-generation high speed submarine and fiber network.
Source: Company Release

Although certain lots of the product were determined to not be in conformity with the approved laboratory specifications, Ranbaxy decided to recall all the lots, as a matter of abundant caution, given its commitment to the health and safety of patients.  Ranbaxy is continuing to look into the cause of such non-conformity.   

The recall is being conducted in coordination with the FDA and will be a retail level recall.  To the best of Ranbaxy’s knowledge, the recalled product is unlikely to produce any serious adverse health effects.  However, there is a remote possibility that the non-conforming product may increase the incidence of local non-serious gastrointestinal adverse events such as nausea and vomiting.  All patients presently consuming and/or prescribed this formulation should consult their physicians for alternate and appropriate medication/treatment options.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India’s largest pharmaceutical company.  RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary “platform technologies,” resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.

Nexret is a next generation anti-acne formulation made from a proprietary non-porous microsphere technology. This unique technology minimizes irritation associated with drugs like Tretinoin and provides controlled delivery of drug to the skin.

Nexret is available in gel formulation and in pack size of 15 gms.

The anti-acne market in India is about Rs 130 crores growing at the rate of about 14%.(Source: ORG IMS)

Source: Company Release

With a gross revenue of over Rs. 45500 crore, provisional unaudited sales of Rs 42182 crore and profit after tax of Rs 7414 crore in 2008-09, NTPC is the leader in Indian power sector. Company contributed 28.60% of the total electricity generated in the country during 2008-09 with 18.79% share of the total installed capacity of the nation.

Operational excellence is the key to NTPC’s success with fifteen of its coal based stations achieving a PLF of 90% which includes 4 registering PLF of over 95% during 2008-09. Dadri station of NTPC achieved an all time high PLF of 99.36% and Talcher thermal (average age 36years) a PLF of 92.7% during the period.

Source: Press Release